Concomitant use of proton pump inhibitors and clopidogrel in patients with coronary, cerebrovascular, or peripheral artery disease in the factores de riesgo y ENfermedad arterial (FRENA) registry

Journal of Cardiovascular Pharmacology

Volumn 57, Issue 1, 2011, Pages 13-19

  Sánchez Muñoz Torrero, Juan Francisco ^a   Escudero, Domingo ^b   Suárez, Carmen ^c   Sanclemente, Carmen ^d   Pascual, Ma Teresa ^b   Zamorano, José ^a   Trujillo Santos, Javier ^e   Monreal, Manuel ^b  

^a HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e Allergy Section   (Spain)

Author keywords

arterial disease; clopidogrel; Outcome; proton pump inhibitors; secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN II ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LANSOPRAZOLE; OMEPRAZOLE; ORAL ANTIDIABETIC AGENT; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; LIMB ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; CEREBROVASCULAR DISORDERS; CORONARY ARTERY DISEASE; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; REGISTRIES; RETROSPECTIVE STUDIES; STROKE; TICLOPIDINE;

EID: 78951484166     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181fc65e5     Document Type: Article

References (30)

1. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996;348:1329-1339.
2. Vickrey BG, Rector TS, Wickstrom SL, et al. Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke. 2002;33:901-906.
3. Steg PG, Bhatt DL, Wilson PWF, et al; for the REACH Registry Investigators. One-year cardiovascular event-rates in outpatients with atherothrombosis. JAMA. 2007;297:1197-1206.
4. Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol. 2008;52:1038-1039.
5. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009; 180:713-718.
6. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301:937-944.
7. Monreal M, Alvarez L, Vilaseca B, et al. FRENA investigators. Clinical outcome in patients with peripheral artery disease. Results from a prospective registry (FRENA). Eur J Intern Med. 2008;19:192-197.
8. Lopez-Jimenez L, Camafort M, Tiberio G, et al. Secondary prevention of arterial disease in very elderly people: results from a prospective registry (FRENA). Angiology. 2008;59:427-434.
9. Barba R, Bisbe J, Pedrajas JN, et al; FRENA Investigators. Body mass index and outcome in patients with coronary, cerebrovascular, or peripheral artery disease: findings from the FRENA Registry. Eur J Cardiovasc Prev Rehabil. 2009;17:456-463.
10. Dormandy JA, Rutherford B. Management of peripheral arterial disease (PAD). TASC Working Group. Trans Atlantic Inter-Society Consensus (TASC). J Vasc Surg. 2000;31:S1-S96.
11. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
12. Martin DO, Austin H. Exact estimates for a rate ratio. Epidemiology. 1996;7:29-33.
13. Levesque R. Available at: http://pages.infinit.net/rlevesqu/SampleSyntax. htm. Accessed July 28, 2010.
14. Simon T, Verstuyft C, Mary-Krause M, et al; for the French Registry of acute ST-elevation and non-ST elevation myocardial infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:1-13.
15. Dunn SP, Macaulay TE, Brennan DM, et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation. 2008;118: S815.
16. ODonoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and Prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374:989-997.
17. Rassen JA, Choudhry NK, Avorn J, et al. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation. 2009;120:2322-2329.
18. Frere C, Cuisset T, Morange PE, et al. Effect of cytochrome P450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol. 2008;101:1088-1093.
19. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug eluting or bare-metal stents. J Am Coll Cardiol. 2008;51:1925-1934.
20. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51:256-260.
21. Gilard M, Arnaud B, Le Gal G, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Res. 2006;4:2508-2509.
22. Gurbel PA, Lau WC, Tantry US. Omeprazole. A possible new candidate influencing the antiplatelet effect of clopidogrel. J Am Coll Cardiol. 2008; 51:261-263.
23. Siller-Matula JM, Lang I, Christ G, et al. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol. 2008;52: 1557-1563.
24. Siller-Matula JM, Spiel AO, Lang IM, et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J. 2009;157: 148.e1-5.
25. Bhatt DL, Scheiman J, Abraham NS, et al; American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2008;118:1894-1909.
26. Gadelha T, Bisbe J, Toril J, et al; FRENA investigators. Major bleeding events in stable outpatients with coronary, cerebrovascular, or peripheral artery disease. Findings from the FRENA Registry. J Thromb Haemost. 2009;7:1414-1416.
27. Early Communication about an Ongoing Safety Review of clopidogrel bisulfate (marketed as Plavix). Available at: http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm079520.htm. Accessed January 26, 2009.
28. Public Health Advisory: Updated Safety Information About a Drug Interaction Between Clopidogrel Bisulfate (marketed as Plavix) and Omeprazole (marketed as Prilosec and Prilosec OTC). Available at: http://www.fda.gov/Drugs/ DrugSafety/PublicHealthAdvisories/ucm190825.htm. Accessed November 17, 2009.
29. Follow-Up to the January 26, 2009, Early Communication About an Ongoing Safety Review of Clopidogrel Bisulfate (marketed as Plavix) and Omeprazole (marketed as Prilosec and Prilosec OTC). Available at: http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm190784.htm. Accessed November 17, 2009.
30. FDA Drug Safety Communication: Reduced Effectiveness of Plavix (clopidogrel) in Patients Who Are Poor Metabolizers of the Drug. Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm. Accessed March 12, 2010.